Figure 1: Change In Height (cm) From Randomization Visit By Scheduled Week (treatment Group Mean ± Standard Error Of The Mean) (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 01)
Montelukast Sodium
Product Images NDC 66116-503
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 66116-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Montelukast Sodium Structural Formula (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 02)
Figure 2: Fev1 Mean Percent Change From Baseline (u.s. Trial: Montelukast Sodium N = 406; Placebo N = 270) (anova Model) (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 03)
This text shows a table with the mean percent change from baseline for a placebo and Montelukast Sodium treatment at weeks 0, 3, 6, 9, 12, and 15. There is no further information on the context of this table.*
Montelukast Sodium Tablets 10mg #30 (B24549cf 6c14 4e49 8756 5bd6d88ec6b8 04)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
